Form 4 for AVIR Atea Pharmaceuticals, Inc.
Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0000950170-24-010970 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-02 | 2024-02-01 | AVIR | Horga Maria Arantxa | Chief Medical Off | S - Sale+OE | $3.84 | -15.9K | 25.7K | -38% | -$60.9K |
| D | 2024-02-02 | 2024-01-31 | AVIR | Horga Maria Arantxa | Chief Medical Off | M - OptEx | — | +41.5K | 41.5K | New | — |
| D | 2024-02-02 | 2024-01-31 | AVIR | Horga Maria Arantxa | Chief Medical Off | M - OptEx | $0.00 | -41.5K | 83.1K | -33% | $0 |
| D | 2024-02-02 | 2024-01-31 | AVIR | Horga Maria Arantxa | Chief Medical Off | A - Grant | $0.00 | +192.8K | 192.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-01 | S | D | 15,870 | $3.84 | 25,664 | D | — | — | (F2) Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022. |
| 2 | Common | Common Stock | 2024-01-31 | M | A | 41,534 | — | 41,534 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| 3 | Derivative | Restricted Stock Units | 2024-01-31 | M | D | 41,534 | $0.00 | 83,066 | D | — · — to — | 41,534 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F3) The original grant of 124,600 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-01-31 | A | A | 192,800 | $0.00 | 192,800 | D | $4.16 · — to 2034-01-30 | 192,800 Common Stock | (F4) The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. |